Diagnosis and management of peritoneal metastases from ovarian cancer

Gastroenterology Research and Practice

Volumn , Issue , 2012, Pages

  Halkia, Evgenia ^a   Spiliotis, John ^a   Sugarbaker, Paul ^b  

^a METAXA Cancer Memorial Hospital   (Greece)

^b WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; BELINOSTAT; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CATHEPSIN L; DOXORUBICIN; ETOPOSIDE; GELATINASE A; GELATINASE B; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; TEMSIROLIMUS; UVOMORULIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADVANCED CANCER; APOPTOSIS; BLOATING; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG HYPERSENSITIVITY; ECHOGRAPHY; HUMAN; INDIGESTION; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEAL FLUID; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; REVIEW;

EID: 84864952501     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2012/541842     Document Type: Review

References (112)

1. American Cancer Society, Cancer facts and figures. 2010, http://www.cancer.org/acs/
2. Liu J., Matulonis U. A., New advances in ovarian cancer Oncology 2010 24 8 691 698
3. Horner M. J., Ries L. A. G., Krapcho M., SEER Cancer Statistics Review 19752006 2010 Bethesda, Md, USA. http://seer.cancer.gov/csr/19752006/
4. Heintz A. P., Odicino F., Maisonneuve P., Carcinoma of the ovary FIGO 6th annual report on the results of treatment in Gynecological cancer International Journal of Gynecology Obstetrics 2006 supplement I 161 192
5. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. J., Cancer statistics, 2009 CA Cancer Journal for Clinicians 2009 59 4 225 249
6. Gadducci A., Landoni F., Sartori E., Maggino T., Zola P., Gabriele A., Rossi R., Cosio S., Fanucchi A., Tisi G., Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a Cooperation Task Force (CTF) study Gynecologic Oncology 2001 81 2 150 159 (Pubitemid 32424153)
7. Tavassoli F. A., Tavassoli F. A., Devilee P., Pathology and Genetics of tumors of the breast and Female genital organs World Health Organization Classification of Tumors 2003 Lyon, France France IARC Press
8. Spiliotis J. D., Peritoneal carcinomatosis cytoreductive surgery and HIPEC: a ray of hope for cure Hepato-Gastroenterology 2010 57 102-103 1173 1177
9. Tuma R. S., Origin of ovarian cancer may have implications for screening Journal of the National Cancer Institute 2010 102 1 11 13
10. Eisenkop S. M., Spirtos N. M., The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer Gynecologic Oncology 2001 82 1 143 149 (Pubitemid 32634967)
11. AJCC, Ovary and primary peritoneal carcinoma AJCC Cancer Staging Handbook 2009 7th Spinger 501 506
12. Lengyel E., Ovarian cancer development and metastasis The American Journal of Pathology 2010 177 3 1053 1064
13. Gupta G. P., Massagué J., Cancer metastasis: building a framework Cell 2006 127 4 679 695 (Pubitemid 44781029)
14. Huber M. A., Kraut N., Beug H., Molecular requirements for epithelial-mesenchymal transition during tumor progression Current Opinion in Cell Biology 2005 17 5 548 558 (Pubitemid 41267170)
15. Elloul S., Elstrand M. B., Nesland J. M., Tropé C. G., Kvalheim G., Goldberg I., Reich R., Davidson B., Snail, slug, and smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma Cancer 2005 103 8 1631 1643 (Pubitemid 40490024)
16. Burleson K. M., Hansen L. K., Skubitz A. P. N., Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers Clinical and Experimental Metastasis 2005 21 8 685 697 (Pubitemid 40755008)
17. Burleson K. M., Casey R. C., Skubitz K. M., Pambuccian S. E., Oegema T. R., Skubitz A. P. N., Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers Gynecologic Oncology 2004 93 1 170 181 (Pubitemid 38429567)
18. Sehouli J., Senyuva F., Fotopoulou C., Neumann U., Denkert C., Werner L., Glten O.., Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer Journal of Surgical Oncology 2009 99 7 424 427
19. Kenny H. A., Kaur S., Coussens L. M., Lengyel E., The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin Journal of Clinical Investigation 2008 118 4 1367 1379 (Pubitemid 351500430)
20. Kaur S., Kenny H. A., Jagadeeswaran S., Zillhardt M. R., Montag A. G., Kistner E., Yamada S. D., Mitra A. K., Lengyel E., 3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer The American Journal of Pathology 2009 175 5 2184 2196
21. Chen L., Park S. M., Tumanov A. V., Hau A., Sawada K., Feig C., Turner J. R., Fu Y. X., Romero I. L., Lengyel E., Peter M. E., CD95 promotes tumour growth Nature 2010 465 7297 492 496
22. Jee Y. H., Mangala L. S., Fok J. Y., Lin Y. G., Merritt W. M., Spannuth W. A., Nick A. M., Fiterman D. J., Vivas-Mejia P. E., Deavers M. T., Coleman R. L., Lopez-Berestein G., Mehta K., Sood A. K., Clinical and biological significance of tissue transglutaminase in ovarian carcinoma Cancer Research 2008 68 14 5849 5858
23. Nishida N., Yano H., Komai K., Nishida T., Kamura T., Kojiro M., Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma Cancer 2004 101 6 1364 1374 (Pubitemid 39180392)
24. Khalique L., Ayhan A., Whittaker J. C., Singh N., Jacobs I. J., Gayther S. A., Ramus S. J., The clonal evolution of metastases from primary serous epithelial ovarian cancers International Journal of Cancer 2009 124 7 1579 1586
25. AJCC, Fallopian tube Carcinoma AJCC Cancer Staging Handbook 2009 New York, NY, USA Springer 501 506
26. FIGO, Current FIGO staging for cancer of the vagina, fallopian tube, ovary and gestational trophoblastic neoplasia International Journal of Gynecology Obstetrics 2009 105 3 4
27. Heintz A., Odicino F., Maisonneuve P., Carcinoma of the ovary. FIGO 6th annual report of the results of treatment in Gynecological Cancer International Journal of Gynecology Obstetrics 2006 95 supplement 1 S161 S192
28. Jacquet P., Sugarbaker P. H., Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis Cancer Treatment and Research 1996 82 359 374
29. Goff B. A., Mandel L. S., Drescher C. W., Urban N., Gough S., Schurman K. M., Patras J., Mahony B. S., Robyn Andersen M., Development of an ovarian cancer symptom index: possibilities for earlier detection Cancer 2007 109 2 221 227 (Pubitemid 46106236)
30. Andersen M. R., Goff B. A., Lowe K. A., Scholler N., Bergan L., Drescher C. W., Paley P., Urban N., Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer Gynecologic Oncology 2010 116 3 378 383
31. Cannistra S. A., Cancer of the ovary The New England Journal of Medicine 2004 351 24 2519 2529
32. Byrne A. T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J. I., Yancopoulos G. D., Jaffe R. B., Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model Clinical Cancer Research 2003 9 15 5721 5728 (Pubitemid 37499496)
33. Lee E. J., Kim S. H., Kim Y. H., Lee H. J., Is CA-125 an additional help to radiologic findings for differentiation borderline ovarian tumor from stage I carcinoma? Acta Radiologica 2011 52 4 458 462
34. Bradford L. S., Schorge J. O., CA125 screening after risk-reducing salpingo-oophorectomy: are the titers too high, or is it all just too much? Menopause 2011 18 2 123 124
35. Rettenmaier N. B., Rettenmaier C. R., Wojciechowski T., Abaid L. N., Brown J. V., Micha J. P., Goldstein B. H., The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review British Journal of Cancer 2010 103 11 1657 1662
36. Zhang W., Yang H. C., Wang Q., Clinical value of combined detection of serum matrix metalloproteinase-9 heparanose and cethepsin for determining ovarian cancer invasion and metastasis Anticancer Research 2011 31 10 3423 3428
37. No J. H., Jeon Y. T., Kim Y. B., Song Y. S., Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer Gynecologic and Obstetric Investigation 2011 71 2 136 140
38. Funt S. A., Hricak H., Abu-Rustum N., Mazumdar M., Felderman H., Chi D. S., Role of CT in the management of recurrent ovarian cancer American Journal of Roentgenology 2004 182 2 393 398 (Pubitemid 38116581)
39. Rauh-Hain J. A., Olawaiye A. B., Munro E. G., Ko E., Alarcon I. A., Del Carmen M. G., Duska L., Role of computed tomography in the surgical management of patients with bowel obstruction secondary to recurrent ovarian carcinoma Annals of Surgical Oncology 2010 17 3 853 860
40. Chandrashekhara S. H., Thulkar S., Srivastava D. N., Kumar L., Hariprasad R., Kumar S., Sharma M. C., Pre-operative evaluation of peritoneal deposits using multidetector computed tomography in ovarian cancer British Journal of Radiology 2011 84 997 38 43
41. Klostergaard J., Parga K., Raptis R. G., Current and future applications of magnetic resonance imaging (MRI) to breast and ovarian cancer patient management Puerto Rico Health Sciences Journal 2010 29 3 223 231
42. Kyriazi S., Collins D. J., Morgan V. A., Giles S. L., deSouza N. M., Diffusion-weighted imaging of peritoneal disease for noninvasive staging of advanced ovarian cancer Radiographics 2010 30 5 1269 1285
43. Cookley F. V., Staging ovarian cancer: role of imaging Radiologic Clinics of North America 2002 40 3 609 636
44. Fulham M. J., Carter J., Baldey A., Hicks R. J., Ramshaw J. E., Gibson M., The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project Gynecologic Oncology 2009 112 3 462 468
45. Sala E., Kataoka M., Pandit-Taskar N., Ishill N., Mironov S., Moskowitz C. S., Mironov O., Collins M. A., Chi D. S., Larson S., Hricak H., Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival Radiology 2010 257 1 125 134
46. Chi D. S., Musa F., Dao F., An analysis of patients with bulky advanced stage ovarian, tubal and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neo-adjuvant chemotherapy Gynecologic Oncology 2012 124 10 14
47. du Bois A., Quinn M., Thigpen T., 2004 consensus statements on the management of ovarian cancer Annals of Oncology 2005 16 8 7 12
48. Harter P., Hilpert F., Mahner S., Kommoss S., Heitz F., Du Bois A., Role of cytoreductive surgery in recurrent ovarian cancer Expert Review of Anticancer Therapy 2009 9 7 917 922
49. Sugarbaker P. H., Peritonectomy procedures Cancer Treatment and Research 2007 134 247 264
50. Spiliotis J., Tentes A. A. K., Vaxevanidou A., Korakianitis O. S., Rogdakis A., Mirelis C. G., Datsis A. C., Kekelos S., Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Preliminary results and cost from two centers in Greece Journal of B.U.ON 2008 13 2 205 210 (Pubitemid 351836702)
51. Spiliotis J., Vaxevanidou A., Datsis A., Rogdakis A., Kekelos S., Peritoneal carcinomatosis: intra-operative and post-operative assessment of patients undergoing cytoreduction and HIPEC Hepato-Gastroenterology 2010 57 102-103 1052 1059
52. Sugarbaker P. H., Chang D., Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy Annals of Surgical Oncology 1999 6 8 727 731 (Pubitemid 30013648)
53. du Bois A., Herrstedt J., Hardy-Bessard A. C., Mller H. H., Harter P., Kristensen G., Joly F., Huober J., vall-Lundqvist E., Weber B., Kurzeder C., Jelic S., Pujade-Lauraine E., Burges A., Pfisterer J., Gropp M., Staehle A., Wimberger P., Jackisch C., Sehouli J., Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer Journal of Clinical Oncology 2010 28 27 4162 4169
54. Ozols R. F., Bundy B. N., Greer B. E., Fowler J. M., Clarke-Pearson D., Burger R. A., Mannel R. S., DeGeest K., Hartenbach E. M., Baergen R., Mackey D., Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study Journal of Clinical Oncology 2003 21 17 3194 3200 (Pubitemid 46606249)
55. du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J., Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzinom (AGO-OVAR) and the groupe d'Investigateurs nationaux pour les etudes des cancers de l'Ovaire (GINECO) Cancer 2009 115 6 1234 1244
56. Harter P., du Bois A., The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence Current Opinion in Oncology 2005 17 5 505 514 (Pubitemid 41224935)
57. Bristow R. E., Puri I., Chi D. S., Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis Gynecologic Oncology 2009 112 1 265 274
58. Eisenkop S. M., Friedman R. L., Spirtos N. M., The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma Cancer 2000 88 144 153 (Pubitemid 30027690)
59. Sehouli J., Richter R., Braicu E. I., Bhling K. J., Bahra M., Neuhaus P., Lichtenegger W., Fotopoulou C., Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients Journal of Surgical Oncology 2010 102 6 656 662
60. Zang R. Y., Zhang Z. Y., Li Z. T., Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer Journal of Surgical Oncology 2000 75 24 30
61. Fleming N. D., Cass I., Walsh C. S., Karlan B. Y., Li A. J., CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer Gynecologic Oncology 2011 121 2 249 252
62. Gronlund B., Lundvall L., Christensen I. J., Knudsen J. B., Hgdall C., Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum European Journal of Surgical Oncology 2005 31 1 67 73 (Pubitemid 40103927)
63. Tentes A. A. K., Korakianitis O. S., Kakolyris S., Kyziridis D., Veliovits D., Karagiozoglou C., Sgouridou E., Moustakas K., Cytoreductive surgery and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer Tumori 2010 96 3 411 416
64. Harter P., du Bois A., Hahmann M., Hasenburg A., Burges A., Loibl S., Gropp M., Huober J., Fink D., Schrder W., Muenstedt K., Schmalfeldt B., Emons G., Pfisterer J., Wollschlaeger K., Meerpohl H. G., Breitbach G. P., Tanner B., Sehouli J., Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial Annals of Surgical Oncology 2006 13 12 1702 1710 (Pubitemid 44951480)
65. Harter P., Hahmann M., Lueck H. J., Poelcher M., Wimberger P., Ortmann O., Canzler U., Richter B., Wagner U., Hasenburg A., Burges A., Loibl S., Meier W., Huober J., Fink D., Schroeder W., Muenstedt K., Schmalfeldt B., Emons G., Du Bois A., Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP i trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis Annals of Surgical Oncology 2009 16 5 1324 1330
66. Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., Mahner S., Vergote I., Reinthaller A., Burges A., Hanker L., Plcher M., Kurzeder C., Canzler U., Petry K. U., Obermair A., Petru E., Schmalfeldt B., Lorusso D., Du Bois A., Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II International Journal of Gynecological Cancer 2011 21 2 289 295
67. Chi D. S., Zivanovic O., Levinson K. L., Kolev V., Huh J., Dottino J., Gardner G. J., Leitao M. M., Levine D. A., Sonoda Y., Abu-Rustum N. R., Brown C. L., Barakat R. R., The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas Gynecologic Oncology 2010 119 1 38 42
68. Scarabelli C., Gallo A., Zarrelli A., Visentin C., Campagnutta E., Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival Gynecologic Oncology 1995 56 3 328 337
69. Panici P. B., Maggioni A., Hacker N., Landoni F., Ackermann S., Campagnutta E., Tamussino K., Winter R., Pellegrino A., Greggi S., Angioli R., Manci N., Scambia G., Dell'Anna T., Fossati R., Floriani I., Rossi R. S., Grassi R., Favalli G., Raspagliesi F., Giannarelli D., Martella L., Mangioni C., Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial Journal of the National Cancer Institute 2005 97 8 560 566 (Pubitemid 40723783)
70. Gerestein C. G., Nieuwenhuyzen-de Boer G. M., Eijkemans M. J., Kooi G. S., Burger C. W., Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer European Journal of Cancer 2010 46 1 102 109
71. Woelber L., Jung S., Eulenburg C., Mueller V., Schwarz J., Jaenicke F., Mahner S., Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer European Journal of Surgical Oncology 2010 36 6 583 588
72. Gerestein C. G., Damhuis R. A. M., Burger C. W., Kooi G. S., Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review Gynecologic Oncology 2009 114 3 523 552
73. Armstrong D. K., Bundy B., Wenzel L., Huang H. Q., Baergen R., Lele S., Copeland L. J., Walker J. L., Burger R. A., Mackey D., Intraperitoneal cisplatin and paclitaxel in ovarian cancer The New England Journal of Medicine 2006 354 1 34 43 (Pubitemid 43048949)
74. Dizon D. S., Hensley M. L., Poynor E. A., Sabbatini P., Aghajanian C., Hummer A., Venkatraman E., Spriggs D. R., Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer Journal of Clinical Oncology 2002 20 5 1238 1247 (Pubitemid 34177430)
75. Parmar M. K., Ledermann J. A., Colombo N., Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer the ICON 4/AGO-OVAR 2.2 trial The Lancet 2003 361 2099 2106
76. Pfisterer J., Plante M., Vergote I., Du Bois A., Hirte H., Lacave A. J., Wagner U., Sthle A., Stuart G., Kimmig R., Olbricht S., Le T., Emerich J., Kuhn W., Bentley J., Jackisch C., Lck H. J., Rochon J., Zimmermann A. H., Eisenhauer E., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG Journal of Clinical Oncology 2006 24 29 4699 4707 (Pubitemid 46630933)
77. Sfakianos G. P., Havrilesky L. J., A review of cost-effectiveness studies in ovarian cancer Cancer Control 2011 18 1 59 64
78. Benedetti Panici P., de Vivo A., Bellati F., Manci N., Perniola G., Basile S., Muzii L., Angioli R., Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer Annals of Surgical Oncology 2007 14 3 1136 1142
79. Gardner G. J., Jewell E. L., Current and future directions of clinical trials for ovarian Cancer Cancer Control 2011 18 1 44 51
80. Burger R. A., Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies Journal of Gynecologic Oncology 2010 21 1 3 11
81. Garcia A. A., Hirte H., Fleming G., Yang D., Tsao-Wei D. D., Roman L., Groshen S., Swenson S., Markland F., Gandara D., Scudder S., Morgan R., Chen H., Lenz H. J., Oza A. M., Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia Journal of Clinical Oncology 2008 26 1 76 82
82. Behbakht K., Sill M. W., Darcy K. M., Rubin S. C., Mannel R. S., Waggoner S., Schilder R. J., Cai K. Q., Godwin A. K., Alpaugh R. K., Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study Gynecologic Oncology 2011 123 1 19 26
83. Phase II randomized, double blind, multicentre study to assess the efficacy of AZD, 2281 in the treatment of patients with platinum sensitive ovarian cancer following treatment with two or more platinum regimens. NCT00753545, 2010, http://clinicaltrials.gov/ct2/show/NCT00753545
84. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinumresistant ovarian, fallopian tube, or primary peritoneal cancer. NCT00993616, 2010, http://clinicaltrials.gov/ct2/show/ NCT00993616
85. Loggie B. W., Sterchi J. M., Rogers A. T., Lentz S., Holmesle H., Charles D., Sundberg D., Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers Regional Cancer Treatment 1995 7 2 78 81
86. Spiliotis J., Vaxevanidou A., Sergouniotis F., Lambropoulou E., Datsis A., Christopoulou A., The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study Journal of B.U.ON 2011 16 1 74 79
87. Helm C. W., Richard S. D., Pan J., HIPEC in ovarian cancer: first report of HYPER-O registry International Journal of Gynecological Cancer 2010 20 1 61 69
88. Rowan K., Intraperitoneal therapy for ovarian cancer: why has it not become standard? Journal of the National Cancer Institute 2009 101 11 775 777
89. Rufian S., Munoz-Casares F. C., Briceno J., Radical surgeryperitonectomy and intra-operative intra-peritoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer Journal of Surgical Oncology 2006 94 4 316 324 (Pubitemid 44330855)
90. Deraco M., Kusomura S., Virzi S., Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy as up front therapy for advanced. EOC: multi-institutional phase II study Gynecologic Oncology 2011 122 2 215 220
91. Deraco M., Baratti D., Laterza B., Balestra M. R., Mingrone E., MacR A., Virz S., Puccio F., Ravenda P. S., Kusamura S., Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer European Journal of Surgical Oncology 2011 37 1 4 9
92. Jaaback K., Johnson N., Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer Cochrane Database of Systematic Reviews 2006 1
93. Vergote I., Trope C. G., Amant F., Neo-adjuvant chemotherapy or primary surgery in stage IIIc or IV ovarian cancer The New England Journal of Medicine 2010 363 10 943 953
94. Spiliotis J., Halkia E., Efstathiou E., Peritoneal carcinomatosis 2011. Is about time for chemosurgery? Journal of B.U.ON 2011 16 400 408
95. Galaal K., Naik R., Bristow R. E., Patel A., Bryant A., Dickinson H. O., Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer Cochrane Database of Systematic Reviews 2010 6
96. Study comparing tumor debulking surgery versus chemotherapy alone in recurrent platinum-sensitive ovarian cancer. AGOOVAR OP4 DESKTOP III, NCT01166737
97. Deraco M., Rossi C. R., Pennacchioli E., Guadagni S., Somers D. C., Santoro N., Raspagliesi F., Kusamura S., Vaglini M., Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study Tumori 2001 87 3 120 126 (Pubitemid 32660378)
98. Zanon C., Clara R., Chiappino I., Bortolini M., Cornaglia S., Simone P., Bruno F., De Riu L., Airoldi M., Pedani F., Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer World Journal of Surgery 2004 28 10 1040 1045 (Pubitemid 40109891)
99. Raspagliesi F., Kusamura S., Campos Torres J. C., de Souza G. A., Ditto A., Zanaboni F., Younan R., Baratti D., Mariani L., Laterza B., Deraco M., Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan European Journal of Surgical Oncology 2006 32 6 671 675 (Pubitemid 44063998)
100. Helm C. W., Randall-Whitis L., Martin R. S., Metzinger D. S., Gordinier M. E., Parker L. P., Edwards R. P., Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma Gynecologic Oncology 2007 105 1 90 96 (Pubitemid 46441446)
101. Di Giorgio A., Naticchioni E., Biacchi D., Sibio S., Accarpio F., Rocco M., Tarquini S., Di Seri M., Ciardi A., Montruccoli D., Sammartino P., Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer Cancer 2008 113 2 315 325
102. Fagotti A., Paris I., Grimolizzi F., Fanfani F., Vizzielli G., Naldini A., Scambia G., Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study Gynecologic Oncology 2009 113 3 335 340
103. Carrabin N., Mithieux F., Meeus P., Trédan O., Guastalla J. P., Bachelot T., Labidi S. I., Treilleux I., Rivoire M., Ray-Coquard I., Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer Bulletin du Cancer 2010 97 4 E23 E32
104. Helm C. W., The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer Oncologist 2009 14 7 683 694
105. Bae J. H., Lee J. M., Ryu K. S., Lee Y. S., Park Y. G., Hur S. Y., Ahn W. S., Namkoong S. E., Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery Gynecologic Oncology 2007 106 1 193 200 (Pubitemid 46898592)
106. Gori J., Castao R., Toziano M., Hbich D., Staringer J., De Quirs D. G. B., Felci N., Intraperitoneal hyperthermic chemotherapy in ovarian cancer International Journal of Gynecological Cancer 2005 15 2 233 239 (Pubitemid 40396958)
107. Fagotti A., Costantini B., Vizzielli G., Perelli F., Ercoli A., Gallotta V., Scambia G., Fanfani F., HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome Gynecologic Oncology 2011 122 2 221 225
108. Smeenk R. M., Verwaal V. J., Zoetmulder F. A. N., Learning curve of combined modality treatment in peritoneal surface disease British Journal of Surgery 2007 94 11 1408 1414 (Pubitemid 350144391)
109. Pomel C., Ferron G., Lorimier G., Rey A., Lhomme C., Classe J. M., Bereder J. M., Quenet F., Meeus P., Marchal F., Morice P., Elias D., Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study European Journal of Surgical Oncology 2010 36 6 589 593
110. Spiliotis J. D., Rogdakis A., Vaxevanidou A., Datsis A., Zacharis G., Christopoulou A., Morbidity and mortality of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis Journal of B.U.ON 2009 14 2 259 264
111. Oxford Center for Evidence Based Medicine,. 2010, http://www.cebm.net/ index.aspx?o=1025
112. Spiliotis J., Halkia E., Roukos D. H., Ovarian cancer screening and peritoneal carcinomatosis: standards, omics and miRNAs for personalized management Expert Review of Molecular Diagnostics 2011 11 5 465 467